Hypermarcas (OTCMKTS:HYPMY) Stock Price Down 7.7% – What’s Next?

Hypermarcas (OTCMKTS:HYPMY)’s share price fell 7.7% during mid-day trading on Wednesday . The company traded as low as $4.78 and last traded at $4.78. 1,053 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 53,135 shares. The stock had previously closed at $5.18.

Hypermarcas Trading Down 3.5%

The company’s 50-day moving average is $4.46 and its 200-day moving average is $4.52. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of 20.39 and a beta of 0.73.

Hypermarcas (OTCMKTS:HYPMY) last announced its earnings results on Wednesday, November 12th. The company reported $0.13 earnings per share for the quarter. Hypermarcas had a net margin of 12.03% and a return on equity of 6.99%. The company had revenue of $408.83 million during the quarter.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.